NetraMark’s AI to Transform Psychiatric Research
Company Announcements

NetraMark’s AI to Transform Psychiatric Research

NetraMark Holdings (TSE:AIAI) has released an update.

NetraMark Holdings Inc. has partnered with the National Institute of Mental Health to boost psychiatric research using their NetraAI platform, which will analyze ketamine clinical trials for psychiatric disorders. The AI-driven analysis aims to enhance precision medicine by identifying key variables that influence treatment outcomes, potentially revolutionizing future clinical trials. This collaboration marks a significant step in integrating AI technology to improve understanding and treatment of complex mental health conditions.

For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskNetraMark Appoints Oncology Expert P.J. Haley to Board
TipRanks Canadian Auto-Generated NewsdeskNetraMark Unveils New Suite to Revolutionize Clinical Trials
TipRanks Canadian Auto-Generated NewsdeskNetraMark’s Q3 Success with AI Clinical Trial Analytics
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App